Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
WATERTOWN, Mass., Oct.
The post Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 appeared first on ForexTV.
Similar Posts
Line Break Chart MT4 Indicator – ForexMT4Indicators.com
Have you ever felt overwhelmed by the constant chatter on your MT4 charts? Price flickering back and forth, candlesticks forming complex patterns – it can be tough to decipher the underlying market sentiment. Fear not, fellow trader! The Line Break Chart MT4 Indicator can be your secret weapon for bringing clarity and focus to your…
XRP/USD Surges Over 400% This Month
As the XRP/USD chart indicates, Ripple’s token price has soared by more than 400% since the beginning of the month, reaching price levels last seen in 2018. This significant growth began in early November as a response to the Republican victory in the US elections. Meanwhile, the XRP/USD rate has been growing much faster than…
UK PM Starmer expected to announce Brexit ”reset” deal on Monday. (Is Brexin the word?) | Forexlive
The UK Times (gated) interview with Prime Minister Starmer. From the report (bolding is mine): The prime minister is expected to announce broad plans for a youth mobility deal on Monday as part of a wider agreement with the European Union The deal will bring Britain into the closest alignment with the EU since Brexit…
AUD/USD Forecast: Jobs Miss Boosts RBA Rate Cut Bets – Forex Crunch
The AUD/USD forecast indicates a surge in RBA rate cut bets. Australia’s economy added only 2,000 jobs, compared to the forecast of 21,000. Reports revealed that Trump was planning to fire Powell. The AUD/USD forecast indicates a surge in RBA rate cut bets after a downbeat jobs report from Australia. Meanwhile, in the US, tensions…
C4X Discovery receives latest milestone payment from Sanofi
€8 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme 27 May 2025 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it has received a milestone payment of €8 million from Sanofi [EPA: SAN], reflecting further pre-clinical progress in the ongoing oral IL-17A inhibitor programme. This…
